- Home
- CNNE vs CVAC Comparison
CNNE vs CVAC Comparison
Compare CNNE & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNNE
- CVAC
- Stock Information
- Founded
- CNNE 2014
- CVAC 2000
- Country
- CNNE United States
- CVAC Germany
- Employees
- CNNE N/A
- CVAC N/A
- Industry
- CNNE Restaurants
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- CNNE Consumer Discretionary
- CVAC Health Care
- Exchange
- CNNE Nasdaq
- CVAC Nasdaq
- Market Cap
- CNNE 1.1B
- CVAC 1.2B
- IPO Year
- CNNE N/A
- CVAC 2020
- Fundamental
- Price
- CNNE $19.48
- CVAC $5.36
- Analyst Decision
- CNNE Buy
- CVAC Hold
- Analyst Count
- CNNE 3
- CVAC 3
- Target Price
- CNNE $23.33
- CVAC $6.83
- AVG Volume (30 Days)
- CNNE 662.7K
- CVAC 475.8K
- Earning Date
- CNNE 11-11-2025
- CVAC 11-11-2025
- Dividend Yield
- CNNE 3.08%
- CVAC N/A
- EPS Growth
- CNNE N/A
- CVAC N/A
- EPS
- CNNE N/A
- CVAC 1.01
- Revenue
- CNNE $437,200,000.00
- CVAC $599,540,810.00
- Revenue This Year
- CNNE N/A
- CVAC N/A
- Revenue Next Year
- CNNE N/A
- CVAC $23.95
- P/E Ratio
- CNNE N/A
- CVAC $5.32
- Revenue Growth
- CNNE N/A
- CVAC 675.15
- 52 Week Low
- CNNE $15.92
- CVAC $2.37
- 52 Week High
- CNNE $22.36
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- CNNE 56.46
- CVAC 46.28
- Support Level
- CNNE $18.85
- CVAC $5.32
- Resistance Level
- CNNE $19.44
- CVAC $5.41
- Average True Range (ATR)
- CNNE 0.42
- CVAC 0.04
- MACD
- CNNE 0.17
- CVAC -0.00
- Stochastic Oscillator
- CNNE 77.41
- CVAC 44.44
About CNNE Cannae Holdings Inc.
Cannae Holdings Inc is a holding company that manages and operates a group of companies and investments. The company's reportable segments are Restaurant Group, Dun & Bradstreet, Alight, BKFC, Corporate and Other. Majority of the company's revenue is generated from its Restaurant Group segment which represents the operations of O'Charley's and Ninety Nine Restaurants.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.